Advisory Committees

Nature and Basis Statements of Conflict(s) of Interest for Voting Members of FDA Advisory Committee Members

The Agency is revising its procedures regarding the disclosure of conflicts of interest and waivers for voting advisory committee members in order to implement the requirements of section 795 of Pub. L. No. 109-97 (Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006) (Nov. 10, 2005). This information is being provided as an interim measure to comply with the requirements of this law.

Advisory Committee for Pharmaceutical Sciences, Clinical Pharmacology Subcommittee (CDER)

November 14-15, 2005

Jeffrey Barrett, Ph.D. (PDF 51KB)

Michael Caldwell, M.D., Ph.D. (1) (PDF 45 KB)

Michael Caldwell, M.D., Ph.D. (2) (PDF 82 KB)

Edmund V. Capparelli, Pharm.D. (1) (PDF 60 KB)

Edmund V. Capparelli, Pharm.D. (2) (PDF 35 KB)

David Z. D'Argenio, Ph.D. (PDF 49 KB)

Marie Davidian, Ph.D. (PDF 49 KB)

David Flockhart, M.D., Ph.D. (PDF 44 KB)

Brian Gage, M.D. (1) (PDF 60 KB)

Brian Gage, M.D. (2) (PDF 47 KB)

Carol Gloff, Ph.D. (PDF 54 KB)

William Jusko, Ph.D. (PDF 54 KB)

Gregory L. Kearns, Pharm.D. (PDF 43 KB)

Howard McLeod, Pharm.D. (1) (PDF 60 KB)

Howard McLeod, Pharm.D. (2) (PDF 62 KB)

Mary Relling, Pharm.D. (PDF 44 KB)

Wolfgang Sadee, Ph.D. (PDF 46 KB)

Nozer D. Singpurwalla, Ph.D. (PDF 46 KB)

Page updated: January 5, 2006